Navigation Links
Pegylated in Medical News

Nektar Announces Agreement With Baxter to Develop New PEGylated Therapeutics for Hemophilia

Companies Build on Existing Collaboration For Long Acting Blood Clotting Factors For Hemophilia SAN CARLOS, Calif., Dec. 20 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR ) today announced a new agreement with subsidiaries of Baxter International Inc. to d...

PEGINTRON(TM) and REBETOL(R) Approved in European Union for Retreating Hepatitis C Patients Who Failed Previous Pegylated or Non-Pegylated Interferon Therapy

First and Only Peginterferon Therapy Approved for Retreating Both Hepatitis C Relapsers and Nonresponders KENILWORTH, N.J., Nov. 15 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP ) today announced that the European Commission on October 30 approved 48-week ...

Savient Pharmaceuticals Receives Complete Response Letter from U.S. Food and Drug Administration for KRYSTEXXA(TM)

...ission. ABOUT KRYSTEXXA (TM) KRYSTEXXA(TM) (pegloticase) is a pegylated uricase enzyme intended for the treatment of chronic gout in patients refra.... Savient has developed one product: KRYSTEXXA(TM) (pegloticase) which is a pegylated uricase enzyme intended for the treatment of chronic gout in patients refra...

New Report Just Published: World Hepatitis C Virus And Therapeutics Market Report

...t - Annual Sales Figures in US$ Million for the Years 2006 through 2015 (includes corresponding Graph/Chart) II-1 Market Overview II-2 pegylated Alpha Interferon Plus Ribavirin - The Standard Therapy II-2 Approved Drugs for HCV Combination Therapy II-2 Table 2: HCV Treatment Market in t...

MDOUTLOOK(R) Quick Polls Report on Clinical Integration of Key Oncology Developments Following ASCO 2009

...eening for Breast Cancer Susceptibility Gene (BRCA) deficiencies. Gynecological Cancers: Combination of carboplatin + pegylated liposomal doxorubicin will be the new standard-of-care for relapsed, platinum-sensitive ovarian cancer For advanced cervical cancer, the combi...

Good news for some hard-to-treat hepatitis C patients

...including liver cancer and death. For patients with chronic hepatitis C, the prognosis varies. About half fully recover after an initial course of pegylated interferon and ribavirin anti-viral therapy that may last from six months to a year. The remaining patients, known as non-responders, may improve ...

Valeant Grants Schering-Plough Exclusive Option in Japan for Taribavirin in Exchange for Release of Last Right of Refusal

...ibavirin in Japan. Taribavirin, a prodrug of ribavirin, is in Phase II development for the treatment of chronic hepatitis C in conjunction with a pegylated interferon. "This agreement with Schering-Plough releases our company from the last right of refusal and provides us more flexibility to pursue...

Telik Presents Results at ASCO From ASSIST-5 Trial of TELCYTA in Platinum Refractory and Resistant Ovarian Cancer

... (ASCO) in Orlando, Florida, of results from the ASSIST-5 Phase 3 randomized, multinational study of TELCYTA(R) (canfosfamide HCl) in combination with pegylated liposomal doxorubicin (PLD) vs. PLD alone in second-line therapy in platinum refractory or resistant ovarian cancer. Study Design : Patients wi...

AGA Institute presents cutting-edge research during DDW

...at re-treated hepatitis C patients who had previously failed treatment with pegylated interferon and ribavirin (patients received treatment with telaprevir combined with pegylated interferon and ribavirin). Another abstract will present the results of...

New treatment option for patients with chronic hepatitis C

...alf of the American Association for the Study of Liver Diseases (AASLD). Nearly half of all HCV patients do not respond to the standard therapy of pegylated interferon and ribavirin. They remain at risk for developing life-threatening liver disease. So far, other alternative therapies have not been particu...
Pegylated in Medical Technology

Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models

- Systemic treatment with chemotherapy and pegylated enzyme produces significantly enhanced survival compared to chemotherapy alone - - Pegylated enzyme well tolerated - SAN DIEGO, July 22 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO ), a biopharma...

Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival

EORTC 18991 Phase III Study Results Published in The Lancet KENILWORTH, N.J., July 11 /PRNewswire-FirstCall/ -- Today, Schering-Plough (NYSE: SGP ) and the EORTC announced that long-term treatment with pegylated interferon alfa-2b in stage III melanoma patients had a significant and sus...

Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference

- New Approach to Targeting the Tumor Microenvironment - SAN DIEGO, April 15 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO ), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced new pre-clinical ...

Idenix Reports Results from Two Phase IIb Studies of the Combination of Valopicitabine and Pegylated Interferon in Hepatitis C Genotype-1 Patients at the 42nd Annual Meeting of the European Association for the Study of the Liver

Additional Preclinical Data Presented on Valopicitabine Combined with an Investigational Protease Inhibitor BARCELONA, Spain, April 12, 2007 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. today announced results from two phase IIb studies of the novel combination of valopicitabine (NM283) ...

Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival

-- EORTC 18991 Phase III Study Results Presented At ASCO -- CHICAGO – June 2, 2007 – Long-term treatment with pegylated interferon alfa-2b in stage III melanoma had a significant and sustained impact on relapse-free survival (RFS), according to the results of the largest adjuvant tri...

Nektar Therapeutics Reports Second Quarter 2009 Financial Results

...ing developed to treat opioid-induced constipation (OIC). NKTR-102, pegylated irinotecan, is currently in Phase 2 clinical studies in ovarian, breast and colorectal cancer. NKTR-105, pegylated docetaxel, is currently in a Phase 1 study in patients with refractory soli...

Idenix Pharmaceuticals Successfully Completes Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)

...f-concept study in HCV-infected patients, we plan to advance IDX184 into a 14-day dose-ranging study in combination with the current standard-of-care, pegylated interferon and ribavirin, to determine the optimal IDX184 doses to advance into broader clinical trials." In the 75 and 100 mg/day cohorts, ...

Telik Announces Presentation at ASCO Annual Meeting

...zed clinical study of canfosfamide (TELCYTA(R), TLK286) in combination with pegylated liposomal doxorubicin (PLD) vs. PLD will be presented at the 45th annual me... "Randomized phase III study of canfosfamide (C, TLK286) plus pegylated liposomal doxorubicin (PLD) versus PLD as second-line therapy...

Video: Partnership Unites UCB with Consumer Product Innovator OXO(R)

...ion site pain (<2%) and a low level of discontinuations due to adverse events (5%). About CIMZIA (R) CIMZIA (R) is the only pegylated anti-TNF (Tumour Necrosis Factor). Cimzia (R) has a high affinity for human TNF-alpha, selectively neutralising the pathophysiological effects of T...

Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting

...ients with the following characteristics are less likely to benefit from retreatment after failing a course of therapy: previous nonresponse, previous pegylated interferon treatment, significant bridging fibrosis or cirrhosis, and genotype 1 infection. (3) No safety and efficacy data are available for treatmen...
Pegylated in Biological News

Biolex presents Locteron US Phase 2a hepatitis C data at EASL

...ects, including flu-like symptoms, associated with pegylated interferons, the current standard of care. Biolex ...of Locteron, and to directly compare Locteron with pegylated interferon. Patients were randomized to receive ei...rofile and dosing convenience compared to existing pegylated interferon products. In contrast to Locteron's con...

Promising new treatment option for women with recurrent ovarian cancer

... Combining the new drug trabectedin with pegylated liposomal doxorubicin provides clinical benefit to... after first-line therapy. Half the women received pegylated liposomal doxorubicin 30 mg/m2 over 60 min plus tr...over 3 hours every 3 weeks, the remainder received pegylated liposomal doxorubicin 50 mg/m2 alone every 4 weeks...

American Chemical Society's Weekly PressPac -- Nov. 7, 2007

...ment, the researchers indicate. ARTICLE #1 FOR IMMEDIATE RELEASE "Conjugation to Increase Treatment Volume during Local Therapy: A Case Study with pegylated Camptothecin" DOWNLOAD PDF http://pubs.acs.org/cgi-bin/sample.cgi/bcches/asap/pdf/bc700214h.pdf DOWNLOAD HTML http://pubs.acs.org/cgi-bin/sa...

Clearance of hepatitis C viral infection after liver transplantation

...h interferon (IFN) and/or ribavirin before LT. Trying to save the life of the patient, Dr Ichikawa decided to introduce the more powerful medicine, pegylated IFN, in the treatment before liver transplantation. PEGylation is a chemical modification incurring higher water-solubility and higher stability to th...

Novel therapy combinations gain ground in treating hepatitis

...ptidomimetic protease inhibitor, VX-950, has previously shown substantial anti-viral effects in combination with the frequently used hepatitis therapy pegylated interferon (pegIFN). In this study, researchers evaluated the safety and antiviral response of VX-950 in combination with pegIFN and ribavirin (RBV)....
Pegylated in Biological Technology

Telik Announces Top-Line Results From Assist-5 Trial of Telcyta(R) in Combination With Pegylated Liposomal Doxorubicin in Platinum Refractory and Resistant Ovarian Cancer

PALO ALTO, Calif., Oct. 29 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK ) today announced top-line results from an interrupted Phase 3 randomized study of Telcyta (canfosfamide HCL) in combination with pegylated liposomal doxorubicin (PLD) versus PLD alone in second-line therapy in pla...

Nektar Therapeutics to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference in New York City

...ing developed to treat opioid-induced constipation (OIC). NKTR-102, pegylated irinotecan, is currently in Phase 2 clinical studies in ovarian, breast and colorectal cancer. NKTR-105, pegylated docetaxel, is currently in a Phase 1 study in patients with refractory soli...

Nektar to Announce Financial Results for the Second Quarter of 2009 on Tuesday, August 4, 2009, After Close of U.S.-Based Financial Markets

...is being developed to treat opioid-induced constipation (OIC). NKTR-102, pegylated irinotecan, is currently in Phase 2 clinical studies in ovarian, breast and colorectal cancer. NKTR-105, pegylated docetaxel, is currently in a Phase 1 study in patients with refractory soli...

Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients

...ys Pharmaceuticals, Inc. (Nasdaq: ANDS ) today announced finalization of the protocol for the Company's Phase II trial of ANA598 in combination with pegylated interferon-alpha and ribavirin in hepatitis C patients. Allowance of the protocol has been received from the United States Food and Drug Administrati...

Anadys Pharmaceuticals Reports Second Quarter 2009 Financial Results and Program Highlights

...d development of ANA598, in particular a Phase II study in combination with pegylated interferon-alpha and ribavirin. The restructuring included a reduction in...received FDA clearance for the Phase II study of ANA598 in combination with pegylated interferon-alpha and ribavirin for the treatment of chronic hepatitis C. I...

Idenix Pharmaceuticals Reports Second Quarter and Six Month 2009 Financial Results

...Ph.D., chairman and chief executive officer of Idenix. "As we work through the second half of the year, we plan to evaluate IDX184 in combination with pegylated interferon and ribavirin in a 14-day dose-ranging study. Additionally, we plan to file investigational new drug applications from our non-nucleoside p...

FDA Appointed Arthritis Advisory Committee Recommends U.S. Food and Drug Administration Approval for KRYSTEXXA(TM) for Refractory Chronic Gout

...ory Committee appointed by the U.S. Food and Drug Administration (FDA) recommended by a vote of 14 to 1 that KRYSTEXXA(TM) (pegloticase), a biologic pegylated uricase enzyme, be granted marketing approval by the FDA for the treatment of refractory chronic gout. Refractory chronic gout or treatment failure g...

Three Rivers Announces Positive Results from Phase 3 DIRECT Trial of Once-Daily INFERGEN(R) with Ribavirin in Hepatitis C Virus Treatment Failures

...e (SVR), was achieved demonstrating that INFERGEN provides a second chance to those HCV patients failing to respond to standard, first-line therapy of pegylated interferon (PEG-IFN) plus ribavirin (RBV). "The retreatment of PEG-IFN/RBV nonresponders with INFERGEN and RBV is safe and efficacious and can be con...

Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Chief Medical Officer

...being developed to treat opioid-induced constipation (OIC). NKTR-102, pegylated irinotecan, is currently in Phase 2 clinical studies in ovarian, breast and colorectal cancer. NKTR-105, pegylated docetaxel, is currently in a Phase 1 study in patients with refractory soli...

Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598

...ng to focus its operations on the development of ANA598, in particular a proposed Phase II study in hepatitis C patients of ANA598 in combination with pegylated interferon-alpha and ribavirin. As part of this restructuring, the Company intends to suspend further development of ANA773 and is reducing its...
Other Tags
(Date:12/21/2014)... The Oncology Institute of Hope and Innovation hosted their third ... The Hope for the Holidays Toy Drive is a way ... during the holiday season. This year, the toy drive was ... offices. This event continues to be successful year after year. ... managers and assistant managers came out and not only donated ...
(Date:12/20/2014)... BambooIndustry.com is a professional company offering many kinds ... shown its new engineered bamboo flooring collection, and announced ... , BambooIndustry.com’s customers come from many countries in the ... the CEO of the company, the global bamboo flooring ... few years, and the demand for eco-friendly bamboo flooring ...
(Date:12/20/2014)... (PRWEB) December 21, 2014 MissyDress, a ... for all prom lovers. The business has drastically cut ... prom dresses to everyone until Jan. 30, 2015. Many ... dresses, sweetheart dresses, V-neck dresses, lace dresses, and more. ... are not there every day. Whether A-line princess prom ...
(Date:12/20/2014)... 20, 2014 An improving macroeconomic landscape ... benefited the Massage Services industry over the ... industry products, the anticipated 1.0% annualized increase in per ... consumers with the means to afford additional massages. “While ... massage in a given year has declined from 2009 ...
(Date:12/20/2014)... New York, NY (PRWEB) December 20, 2014 ... ) that allege a metal-on-metal version of the ... move forward in state and federal courts, Bernstein ... in New Jersey’ Bergen County Superior Court on ... were permitted to begin deposition of plaintiffs on ...
Breaking Medicine News(10 mins):Health News:BammbooIndustry.com: Big Discounts On All Kinds Of Bamboo Flooring Collections 2Health News:MissyDress: The Prices of Prom Dresses Just Reduced 2Health News:Massage Services in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Massage Services in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 2Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 3Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 4
(Date:12/11/2014)... 2014  Data Sciences International (DSI), the global ... new series of digital telemetry implants to meet ... series, part of the PhysioTel™ Digital platform, was ... physiologic data when incorporating functional endpoints into repeat-dose ... toxicology studies has evolved from short ECG strips ...
(Date:12/10/2014)... DIEGO , Dec. 9, 2014 CIE ... collaboration catalyst that provides the connective tissue that enhances ... enabling them to easily share client-level information; earned a ... to expand to organizations serving seniors aging in community ... Diego" partner on December 11 th 4-6p. ...
(Date:12/5/2014)... , Dec. 4, 2014  Tute Genomics, a leader ... million in Series A1 funding led by UK-based Eurovestech. ... participated in the investment round. "We are ... community adopts next-generation sequencing and seeks new approaches for ... Reid Robison , MD MBA, and CEO of Tute ...
Breaking Biology News(10 mins):New telemetry implants expected to change how large animal toxicology studies are conducted 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3
Other Contents